ENALARE THERAPEUTICS INC
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.5Mattributed |
|---|---|
| Latest round | grant, $2.5M, 2025-01-01attributed |
| Founded | unknown |
| Headquarters | PRINCETON, New Jersey |
| Industry | bio |
| Stage | unknown |
| Website | enalare.com |
Enalare Therapeutics is developing ENA-001, a patent-protected breathing stimulant for acute respiratory depression. Target indications include opioid-overdose respiratory depression, post-operative respiratory compromise, and apnea of prematurity in infants. The new chemical entity is positioned to provide a non-opioid pharmacologic option for emergency and inpatient settings.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | grant | $2.5M | undisclosed |
Detected tech stack
WordPress 7.0, Apache HTTP Server 2.4.41, Yoast SEO 27.6, Ubuntu, Google Tag Manager, Google Tag Manager for WordPress 1.22.3, Slider Revolution, jQuery Migrate 3.4.1, PHP, Contact Form 7 6.1.6, MySQL, apache 2.4.41
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.5M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $2.5M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | enalare.com, read 2026-05-02 |
| Description | self-reported | enalare.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.